MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Trial Details

NCT ID
NCT07409454
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • anti-BCMA/CD3 bispecific antibody
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be able to understand and voluntarily signs the informed consent form (ICF).
  • Age ≥ 18 years.
  • Newly diagnosed multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.
  • MRD positivity (≥10-⁵) detected by EuroFlow.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →